Director shareholdings

RNS Number : 0872R
Advanced Medical Solutions Grp PLC
24 April 2009



For Immediate release

24 April 2009

Advanced Medical Solutions Group PLC 

(“AMS” or the “Company”)

Directors’ shareholdings

Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the following Directors purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 23 April 2009, as part of the Deferred Share Bonus Plan. These Ordinary Shares were bought at a price of 34 pence per share and, under the terms of the Plan, will be held in trust on their behalf.

Director

Shares purchased

Resultant holding

% of issued share capital

Don Evans, Chief Executive Officer

55,882

849,591

0.59

Mary Tavener, Finance Director

37,352

221,130

0.15

Chris MeredithCommercial Director

37,352

111,890

0.08

In addition, the Board granted new share options to the Directors under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’) on 23 April 2009. These options are subject to certain performance criteria over a three year period to vest.

Director

LTIPs granted

Resultant holding

Don Evans

293,843

3,295,016

Mary Tavener

193,408

2,407,979

Chris Meredith

589,234

1,797,234

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer

Mary Tavener, Finance Director
www.admedsol.com

Tel: +44 (0) 16 0654 5508

Buchanan Communications

Mark Court 

Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Richard Jones

Tim Pratelli

Tel: +44 (0) 20 7597 5970 

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 


This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSCKNKPABKDBQB